Theralase Technologies Inc. (V:TLT) — Market Cap & Net Worth
Market Cap & Net Worth: Theralase Technologies Inc. (TLT)
Theralase Technologies Inc. (V:TLT) has a market capitalization of $60.96 Million (CA$84.27 Million) as of August 4, 2026. Listed on the V stock exchange, this Canada-based company holds position #21060 globally and #729 in its home market, demonstrating a 9.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theralase Technologies Inc.'s stock price CA$0.29 by its total outstanding shares 295671318 (295.67 Million). See Theralase Technologies Inc. capex to cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
Theralase Technologies Inc. Market Cap History: 2015 to 2026
Theralase Technologies Inc.'s market capitalization history from 2015 to 2026. Data shows growth from $91.97 Million to $60.96 Million (0.16% CAGR).
Theralase Technologies Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theralase Technologies Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
44.53x
Theralase Technologies Inc.'s market cap is 44.53 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $54.54 Million | $1.92 Million | -$4.92 Million | 28.42x | N/A |
| 2017 | $52.40 Million | $2.34 Million | -$6.09 Million | 22.37x | N/A |
| 2018 | $67.37 Million | $1.73 Million | -$3.36 Million | 38.85x | N/A |
| 2019 | $72.72 Million | $964.05K | -$7.43 Million | 75.43x | N/A |
| 2020 | $40.64 Million | $929.12K | -$5.61 Million | 43.74x | N/A |
| 2021 | $80.21 Million | $780.64K | -$4.42 Million | 102.74x | N/A |
| 2022 | $68.44 Million | $1.14 Million | -$5.25 Million | 60.11x | N/A |
| 2023 | $38.50 Million | $1.07 Million | -$4.57 Million | 35.97x | N/A |
| 2024 | $56.68 Million | $1.03 Million | -$4.26 Million | 54.85x | N/A |
| 2025 | $36.36 Million | $816.47K | -$4.12 Million | 44.53x | N/A |
Competitor Companies of TLT by Market Capitalization
Companies near Theralase Technologies Inc. in the global market cap rankings as of August 4, 2026.
Key companies related to Theralase Technologies Inc. by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #114 globally with a market cap of $183.80 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #189 globally with a market cap of $124.64 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #233 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #238 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #114 | Abbott Laboratories | NYSE:ABT | $183.80 Billion | $105.70 |
| #189 | Stryker Corporation | NYSE:SYK | $124.64 Billion | $325.70 |
| #233 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #238 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $85.39 |
Theralase Technologies Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Theralase Technologies Inc.'s market cap moved from $91.97 Million to $ 60.96 Million, with a yearly change of 0.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$60.96 Million | +67.65% |
| 2025 | CA$36.36 Million | -35.85% |
| 2024 | CA$56.68 Million | +47.22% |
| 2023 | CA$38.50 Million | -43.75% |
| 2022 | CA$68.44 Million | -14.67% |
| 2021 | CA$80.21 Million | +97.37% |
| 2020 | CA$40.64 Million | -44.12% |
| 2019 | CA$72.72 Million | +7.94% |
| 2018 | CA$67.37 Million | +28.57% |
| 2017 | CA$52.40 Million | -3.92% |
| 2016 | CA$54.54 Million | -40.70% |
| 2015 | CA$91.97 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Theralase Technologies Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $60.96 Million USD |
| MoneyControl | $60.96 Million USD |
| MarketWatch | $60.96 Million USD |
| marketcap.company | $60.96 Million USD |
| Reuters | $60.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Theralase Technologies Inc.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form … Read more